We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

NASDAQ:RYTM opened at $52.91 on Monday. The business’s fifty day moving average is $55.28 and its 200 day moving average is $54.99. The firm has a market cap of $3.35 billion, a price-to ...

Needham raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $66 from $64 and keeps a Buy rating on the shares. The firm sees ...

RHYTHM PHARMACEUTICLS ($RYTM) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of -$0.72 per share, beating estimates of ...